Nektar Therapeutics (NKTR), a developer of immunotherapy medicines, said on Tuesday that it has priced its underwritten public offering of 4.255 million shares at $23.50 per share for gross proceeds of around $100 million.
The drug maker has also granted the underwriters a 30-day option to purchase up to an additional 638,298 shares. The offering is expected to be closed on July 2.
The company intends to use the net proceeds from the offering for research and development, clinical development, and manufacturing costs to support the advancement of its drug candidates, as well as general corporate purposes.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.